Cartesian Therapeutics, Inc.
RNACNASDAQHealthcare● Active
$5.86
+$0.02(+0.34%)
Market Cap$172175590
P/E Ratio—
52W High$15.57
52W Low$5.6
Cartesian Therapeutics, Inc. (RNAC) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RNAC · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($130.30M) | ($77.42M) | ($219.71M) | $35.38M | ($25.69M) |
| Depreciation & Amort. | $2.96M | $1.15M | $0.84M | $1.29M | $1.25M |
| Stock-Based Comp. | $10.52M | $6.58M | $22.52M | $11.19M | $7.72M |
| Change in Working Capital | ($8.06M) | ($5.79M) | $4.97M | ($60.38M) | ($48.19M) |
| Net Cash from Operations | ($73.94M) | ($23.67M) | ($51.16M) | ($31.63M) | ($60.38M) |
| Investing Activities | |||||
| Capital Expenditure | ($5.45M) | ($9.09M) | ($0.21M) | ($1.20M) | ($1.08M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | ($33.50M) | ($32.45M) |
| Sales of Investments | $0.00M | $0.00M | $28.25M | $19.70M | $16.40M |
| Net Cash from Investing | ($5.45M) | ($8.74M) | $34.61M | ($15.00M) | ($17.14M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | ($6.17M) | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | ($27.46M) | $0.00M | $0.00M |
| Net Cash from Financing | ($8.05M) | $168.43M | ($13.14M) | $39.22M | $52.90M |
| Free Cash Flow | |||||
| Free Cash Flow | ($79.39M) | ($32.77M) | ($51.37M) | ($32.83M) | ($61.47M) |
| FCF Margin %(computed) | — | -84.21% | -197.53% | -29.64% | -72.25% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Cartesian Therapeutics, Inc. data
About Cartesian Therapeutics, Inc. (RNAC) Cash Flow Statement
Cartesian Therapeutics, Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.08B) for 2025 — a FCF margin of -2838.58%. Capital expenditure was ($0.01B).
Frequently asked questions
RNAC · 4 questionsCartesian Therapeutics, Inc. generated free cash flow of ($0.08B) for 2025, down 142.3% year-over-year.
RNAC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10